What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to officially announce Abbott Laboratories' financial results for the second quarter of 2020 and to furnish the associated press release (Exhibit 99.1) that contains the detailed results.

Does this filing contain the actual Q2 2020 financial numbers?

The 8-K filing itself does not contain the specific Q2 2020 financial numbers within its text. Instead, it directs investors to Exhibit 99.1, the press release dated July 16, 2020, where these results are disclosed.

What are non-GAAP financial measures, and why does Abbott use them?

Non-GAAP financial measures are financial calculations that exclude certain items from GAAP (Generally Accepted Accounting Principles) figures. Abbott uses them to provide investors with a clearer view of ongoing business performance by adjusting for factors that may be unusual, unpredictable, or not indicative of core operational results, such as acquisition-related expenses or restructuring charges. Management believes these measures aid in assessing performance and comparability.

What should investors be aware of regarding the non-GAAP measures mentioned?

Investors should be aware that Abbott presents these non-GAAP measures to supplement GAAP financial measures. They are advised to consider these non-GAAP figures in addition to, and not as a substitute for, the financial measures prepared in accordance with GAAP, as the GAAP figures represent the company's officially reported financial position and performance.

ABT 8-K: Earnings & Results

Summary

Abbott Laboratories (ABT) filed an 8-K on July 16, 2020, to announce its second quarter 2020 financial results. The report primarily serves to furnish a press release detailing these results. Investors should note that while the press release provides key financial performance metrics, it also utilizes non-GAAP financial measures alongside GAAP figures. Abbott's management emphasizes that these non-GAAP measures, which exclude items like acquisition and restructuring expenses, R&D asset charges, impairments, and certain tax benefits, are used internally for performance assessment and are intended to offer investors a clearer view of ongoing business operations. While specific Q2 2020 figures are not detailed within the 8-K text itself, the filing directs investors to the furnished Exhibit 99.1 press release for comprehensive details. The non-GAAP adjustments are presented to provide investors with additional context and comparability, allowing for a better evaluation of operational performance by removing unusual or unpredictable factors. Investors are advised to consider these non-GAAP measures in conjunction with, and not as a substitute for, the GAAP-prepared financial statements.

Key Highlights

1Abbott Laboratories announced its second quarter 2020 financial results via an 8-K filing on July 16, 2020.
2The filing includes a press release (Exhibit 99.1) containing detailed operational and financial information for Q2 2020.
3Abbott utilizes non-GAAP financial measures in its earnings announcement, alongside GAAP figures.
4Non-GAAP measures exclude items such as acquisition/restructuring costs, R&D asset charges, impairments, and specific tax items.
5Management believes these non-GAAP measures enhance investor understanding of ongoing business performance by removing unusual or unpredictable factors.
6Abbott's CFO, Robert E. Funck, Jr., signed the report, indicating official financial oversight.
7Investors are cautioned to consider non-GAAP measures in addition to, and not as a substitute for, GAAP measures.

ABBOTT LABORATORIES 8-K Report, Financial Results (Jul 16, 2020)

Summary

Key Highlights

Frequently Asked Questions